Founded in 2021 in Oviedo, Pragmatech develops iAST®, an AI-powered clinical decision-support tool that recommends the most appropriate antibiotic treatment and has secured CE marking as a medical device. The software has been clinically validated to cut prescribing errors and suggest therapies with lower resistance potential, addressing both patient outcomes and antimicrobial stewardship. Pragmatech operates on a B2B model, selling directly to hospitals and healthcare systems. With fresh capital in hand, the team plans a broad commercial rollout of iAST® while continuing to refine the algorithm to keep pace with evolving resistance patterns. Co-CEOs Javier Fernández and Pablo Valledor stress that the goal is to embed safe, effective AI into routine infectious-disease management. The company positions itself as a driver of digital transformation in microbiology and pharmacology. The recent €650k raise provides runway for sales expansion and further product development, but no revenue or user metrics have yet been disclosed.

Total raised

$1M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2025